Comparative Pharmacology
Head-to-head clinical analysis: ERYTHROCIN versus ZITHROMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYTHROCIN versus ZITHROMAX.
ERYTHROCIN vs ZITHROMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin is a macrolide antibiotic that binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking translocation of peptidyl-tRNA. It also exhibits anti-inflammatory and prokinetic effects via motilin receptor agonism.
Azithromycin is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by preventing translocation of peptides. It also has immunomodulatory and anti-inflammatory effects.
250-500 mg orally every 6 hours or 500 mg to 1 g intravenously every 6 hours.
500 mg orally once daily for 3 days, or 2 g orally as a single dose for certain infections.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-2 hours in adults; may prolong to 4-6 hours in hepatic impairment or neonates.
Terminal elimination half-life of approximately 68 hours (range 35-96 hours), allowing once-weekly dosing for some indications.
Primarily eliminated via biliary excretion as unchanged drug and metabolites; approximately 2-5% excreted renally as active drug, 15-20% as metabolites; up to 30% excreted in feces.
Primarily eliminated via biliary/fecal route (∼50-60% as unchanged drug); renal excretion accounts for ∼12% of the dose; minimal metabolism.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic